UA140099U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis, including clinical examination, radiography, according to the utility model in addition to the patient's serum determine the polymorphism of the nitric oxide synthase gene (eNOS T786C), the content of endothelin, folic acid, homocysteine, g-interleukin 6 GAG) and with homozygous carrier 786-CC, levels of endothelin> 10 ng / ml, folic acid <6 ng / ml, homocysteine> 20 μmol / l, IL-6> 10 ng / l, GAG> 28 μmol / l predict the development osteoarthritis.

Description

The proposed useful model The method of predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the nitric oxide synthase gene (eMO5 17860), the content of endothelin, folic acid, homocysteine, interleukin 6 (IL-b6), glycosaminoglycans (GAG) are determined in the patient's blood serum homozygous carrier 786-SS, levels of endothelin "10 ng/ml, folic acid "6 ng/ml, homocysteine 220 μmol/l, IL-b6 210 ng/l, GAG 528 μmol/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the polymorphism of the eMmo5 1786C gene is determined, the content of endothelin, folic acid, homocysteine, IL-6, GAG is determined by the immunoenzymatic method. With homozygous carrier 786-SS and levels of endothelin 210 ng/ml, folic acid "6 ng/ml, homocysteine 220 μmol/l, IL-6 "10 ng/l, GAG "28 μmol/l predict the development of osteoarthritis.

A specific example of using the method

Patient 0., 58 years old, was admitted to the clinic due to pain syndrome in the left knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. In blood serum, the eMMO5 1786C gene polymorphism and the content of endothelin, folic acid, homocysteine, IL-b6, and GAG were determined by the immunoenzymatic method. Established homozygous carrier 786-

SS, levels of endothelin - 25 ng/ml, folic acid - 3.6 ng/ml, homocysteine - 39 μmol/l, IL-6-22 ng/l, GAG - 46 μmol/l. The development of osteoarthritis was diagnosed. After 12 months on

X-rays revealed the phenomena of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which differs in that the polymorphism of the nitric oxide synthase gene (6eMOb5 17860), the content of endothelin, folic acid, homocysteine, interleukin 6 (IL-6), glycosaminoglycans (GAG) and with homozygous carrier 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, homocysteine 220 μmol/l, IL-6 "10 ng/l, GAG »28 μmol/l predict the development of osteoarthritis.